- AU$11.84m
- AU$7.07m
- AU$3.40m
- 48
- 37
- 44
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.34 | ||
| Price to Tang. Book | 2.36 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.43% | ||
| Return on Equity | -29.89% | ||
| Operating Margin | -40.89% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 1.08 | 2.34 | 1.11 | 1.58 | 3.4 | n/a | n/a | 46.42% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nyrada Inc. is a preclinical stage, drug development company specializing in small molecule drugs to treat cardiovascular and neurological diseases. The Company’s two lead programs are focused on cholesterol-lowering and brain injury. These programs are developing an oral, small molecule cholesterol-lowering drug, and a drug to reduce secondary brain damage following a stroke or traumatic brain injury (TBI). Its Cholesterol-Lowering Program is an oral PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs. Its Brain Injury Program is developing a drug to block secondary brain damage that occurs following a stroke or TBI, such as severe head trauma from contact sports, a fall, or a motor vehicle accident. The Brain Injury Program is a neuroprotectant drug to reduce the impact of long-term disability in patients who suffer a traumatic brain injury or ischemic stroke. It is also developing new therapies.
Directors
- Last Annual
- June 30th, 2024
- Last Interim
- June 30th, 2024
- Incorporated
- August 29th, 2017
- Public Since
- January 16th, 2020
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 182,208,698
- Address
- Suite 2, Level 3,, 828 Pacific Highway, GORDON, 2072
- Web
- https://www.nyrada.com/site/content/
- Phone
- +61 294983390
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for NYR
Half Year 2025 Nyrada Inc Earnings Release
Similar to NYR
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Nyrada share price?
As of Today at 22:24 UTC, shares in Nyrada are trading at AU$0.07. This share price information is delayed by 15 minutes.
How has the Nyrada share price performed this year?
Shares in Nyrada last closed at AU$0.07 and the price had moved by +195.45% over the past 365 days. In terms of relative price strength the Nyrada share price has outperformed the ASX All Ordinaries Index by +150.37% over the past year.
What are the analyst and broker recommendations for Nyrada?
There is no consensus recommendation for this security.
Find out moreWhat is the Nyrada dividend yield?
Nyrada does not currently pay a dividend.
Does Nyrada pay a dividend?
Nyrada does not currently pay a dividend.
When does Nyrada next pay dividends?
Nyrada does not currently pay a dividend.
How do I buy Nyrada shares?
To buy shares in Nyrada you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nyrada?
As of the previous close price of AU$0.07, shares in Nyrada had a market capitalisation of AU$11.84m.
Where are Nyrada shares listed?
Here are the trading details for Nyrada:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: NYR
What kind of share is Nyrada?
Based on an overall assessment of its quality, value and momentum Nyrada is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nyrada share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Nyrada share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nyrada. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -32.79%.
As of the last closing price of AU$0.07, shares in Nyrada were trading +15.08% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nyrada PE Ratio?
The Nyrada PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nyrada?
We do not have data on Nyrada's directors